Colorectal Cancer in Inflammatory Bowel Disease
Gut and Liver
; : 61-73, 2008.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-112839
Responsible library:
WPRO
ABSTRACT
Patients with long-standing inflammatory bowel disease have an increased risk of developing colorectal cancer (CRC). CRC risk increases with longer duration of colitis, greater anatomic extent of colitis, the presence of primary sclerosing cholangitis, family history of CRC and severity of inflammation of the colon. Chemoprevention includes aminosalicylates, ursodeoxycholic acid, and possibly folic acid. To reduce CRC mortality in IBD, colonoscopic surveillance remains the major way to detect early mucosal dysplasia. When dysplasia is confirmed, proctocolectomy is considered for these patients. Ulcerative colitis patients with total proctocolectomy and ileal pouch anal-anastomosis have a rather low risk of dysplasia in the ileal pouch, but the anal transition zone should be monitored periodically. New endoscopic and molecular screening approaches may further refine our current surveillance guidelines and our understanding of the natural history of dysplasia.
Full text:
Available
Health context:
SDG3 - Health and Well-Being
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Target 3.4: Reduce premature mortality due to noncommunicable diseases
/
Colon and Rectum Cancers
/
Digestive System Diseases
Database:
WPRIM (Western Pacific)
Main subject:
Ursodeoxycholic Acid
/
Cholangitis, Sclerosing
/
Colorectal Neoplasms
/
Inflammatory Bowel Diseases
/
Colitis, Ulcerative
/
Mass Screening
/
Colitis
/
Colon
/
Natural History
/
Chemoprevention
Type of study:
Screening study
Limits:
Humans
Language:
English
Journal:
Gut and Liver
Year:
2008
Document type:
Article